Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-90
SponsorOle Lander Svendsen
About this trial
The aim of this exploratory pilot study is to investigate the effect of semaglutide compared to placebo on healing of foot ulcers in type 2 diabetes patients.
It is a randomized double blind, placebo controlled, clinical intervention study of 20 weeks intervention.
Eligibility criteria
Qualifiers
Diagnosis of type 2 diabetes mellitus for at least 6 months
Age 18-90 years
A foot ulcer below the level of the malleoli. If more than one ulcer, the largest will be selected at screening as the index ulcer.
Wound area after sharp debridement of ≥ 5 mm2, but ≤ 3000 mm2.
Disqualifiers
Current use, or recent use (<3 months), of GLP-1 agonists
Current use of DPP-IV inhibitors
Previous acute pancreatitis
Signs of infection of the index ulcer
Trial design
Treatments tested in this trial
- Semaglutide, 1.34 mg/mL
- Placebo
Treatment groups
52 Participants
are divided into 2 treatment groupsSponsors and collaborators
Ole Lander Svendsen
Lead sponsor
University Hospital Bispebjerg and Frederiksberg
Sponsor institution
Source ClinicalTrials.gov